Want to see CH:CURN full AI Analyst Report?
Top Page
Curatis Holding AG
(CURN)
Select Model
Select Model
Rating:43Neutral
Price Target:
CHF17.50
Action:Reiterated
Date:08/06/26
The score is held back primarily by weak financial quality despite improving operations: losses persist and cash flow remains negative even as revenue and margins recover, though the debt-free balance sheet is a stabilizing factor. Technically, momentum is weak with price below key moving averages and negative MACD. Valuation is also constrained by a negative P/E and no dividend yield data.
Positive Factors
Revenue recovery
The sharp revenue rebound indicates improving commercial traction and renewed demand for the company’s pharmaceutical and healthcare offerings. If maintained, stronger sales can provide operating leverage, support investment in the business, and improve the foundation for eventual profitability over coming quarters.
Negative Factors
Persistent unprofitability
Despite better revenue and margins, the company has not yet converted operating improvement into positive EBIT, EBITDA, or net income. Persistent losses weaken internal capital formation and show that the business still needs further scale or cost improvement before earnings can become durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue recovery
The sharp revenue rebound indicates improving commercial traction and renewed demand for the company’s pharmaceutical and healthcare offerings. If maintained, stronger sales can provide operating leverage, support investment in the business, and improve the foundation for eventual profitability over coming quarters.
Read all positive factors
Curatis Holding AG (CURN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF107.29M
Dividend YieldN/A
Average Volume (3M)1.59K
Price to Earnings (P/E)―
Beta (1Y)-0.88
Revenue Growth32.84%
EPS Growth61.88%
CountryCH
Employees9
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.29
Shares Outstanding5,313,449
10 Day Avg. Volume2,245
30 Day Avg. Volume1,595
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)1.03
Price to Sales (P/S)4.40
P/FCF Ratio-18.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.79
Revenue Forecast (FY)CHF99.00M
Curatis Holding AG Business Overview & Revenue Model
Company Description
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialize...
Curatis Holding AG Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
74
Positive
Cash Flow
32
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.80M | 6.90M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.84M | 1.59M | 0.00 | -1.52M | 0.00 |
| EBITDA | -1.13M | -4.34M | -38.34M | -38.37M | -130.00K |
| Net Income | -1.42M | -4.34M | -49.38M | -34.73M | 137.00K |
Balance Sheet | |||||
| Total Assets | 55.96M | 55.54M | 120.00K | 14.05M | 136.00K |
| Cash, Cash Equivalents and Short-Term Investments | 1.87M | 3.01M | 9.00K | 1.34M | 124.00K |
| Total Debt | 0.00 | 0.00 | 133.00K | 3.00M | 429.00K |
| Total Liabilities | 9.88M | 9.94M | 432.00K | 7.29M | 536.00K |
| Stockholders Equity | 46.08M | 45.60M | -312.00K | 6.75M | -400.00K |
Cash Flow | |||||
| Free Cash Flow | -2.53M | -825.00K | -1.89M | -4.66M | -359.00K |
| Operating Cash Flow | -1.31M | -825.00K | -1.89M | -4.65M | -359.00K |
| Investing Cash Flow | -1.22M | 4.01M | -6.00K | 5.48M | 0.00 |
| Financing Cash Flow | 1.38M | -183.00K | 558.00K | 392.00K | 420.00K |
Curatis Holding AG Technical Analysis
Positive
―
Price Trends
20.55
Negative
21.94
Negative
19.92
Positive
Market Momentum
-0.33
Positive
52.18
Neutral
50.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:CURN, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 19.72, equal to the 50-day MA of 20.55, and equal to the 200-day MA of 19.92, indicating a neutral trend. The MACD of -0.33 indicates Positive momentum. The RSI at 52.18 is Neutral, neither overbought nor oversold. The STOCH value of 50.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:CURN.
Curatis Holding AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.